<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Cardiovascular</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Protuoso Biosciences building multifunctional protein engineering platform</title>
      <description>
        <![CDATA[Protuoso Biosciences has announced the close of an oversubscribed $9.5 million seed financing round, the proceeds of which will be used to advance its multifunctional protein engineering platform and broad pipeline across cardiometabolic, oncology and autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731477</guid>
      <pubDate>Thu, 28 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731477-protuoso-biosciences-building-multifunctional-protein-engineering-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Science-research-drug-development.webp?t=1663858388" type="image/png" medium="image" fileSize="1141393">
        <media:title type="plain">Drug R&amp;D concept image.</media:title>
      </media:content>
    </item>
    <item>
      <title>D&amp;D’s zabopegdutide shows more upbeat top-line phase II MASH data </title>
      <description>
        <![CDATA[D&D Pharmatech Inc. announced May 27 positive top-line tissue biopsy results of zabopegdutide (DD-01) from a 48-week phase II study of metabolic dysfunction-associated steatohepatitis (MASH), pushing company shares up 30% on the day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731423</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731423-d-and-ds-zabopegdutide-shows-more-upbeat-top-line-phase-ii-mash-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-damage-fibrosis-cirrhosis.webp?t=1769528466" type="image/jpeg" medium="image" fileSize="677639">
        <media:title type="plain">Art concept for liver damage, such as fatty liver, fibrosis or cirrhosis</media:title>
      </media:content>
    </item>
    <item>
      <title>Circio and Aavigen to collaborate on targeted cardiac AAVs</title>
      <description>
        <![CDATA[Circio Holding ASA and Aavigen GmbH have entered a research collaboration focused on developing circVec-enhanced AAV vectors engineered for targeted, low-dose gene therapies for heart diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731292</guid>
      <pubDate>Wed, 27 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731292-circio-and-aavigen-to-collaborate-on-targeted-cardiac-aavs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-and-DNA.webp?t=1629916296" type="image/png" medium="image" fileSize="441817">
        <media:title type="plain">Heart and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Lilly buys three vaccine makers; PCSK9 base editor shows promise</title>
      <description>
        <![CDATA[As the most active biopharma acquirer of 2026, Eli Lilly and Co. offered to buy three vaccine companies for up to $3.8 billion combined, while it simultaneously released positive early clinical results of a gene editing medicine brought into the fold last year through its buyout of Verve Therapeutics Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731401</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731401-lilly-buys-three-vaccine-makers-pcsk9-base-editor-shows-promise</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Syringes-in-virus-cell-company-logos.webp?t=1779831670" type="image/png" medium="image" fileSize="273178">
        <media:title type="plain">Syringes in virus cell; Lilly, Curevo, Limmatech, Vaccine Company   logos</media:title>
      </media:content>
    </item>
    <item>
      <title>Scribe’s STX-1150 for hypercholesterolemia cleared for clinic</title>
      <description>
        <![CDATA[Scribe Therapeutics Inc. has obtained clearance from Australia’s Therapeutic Goods Administration (TGA) to initiate a first-in-human study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD). The phase I study will enroll adults with elevated LDL-C at increased cardiovascular risk at sites in Australia and New Zealand.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731249</guid>
      <pubDate>Fri, 22 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731249-scribes-stx-1150-for-hypercholesterolemia-cleared-for-clinic</link>
    </item>
    <item>
      <title>Nampt activators disclosed in Nanjing Reju Therapeutics patent </title>
      <description>
        <![CDATA[Nanjing Reju Therapeutics Inc. has reported new nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) activators potentially useful for the treatment of atherosclerosis, Duchenne muscular dystrophy, heart failure, multiple sclerosis, obesity, cardiomyopathy, Alzheimer’s and Parkinson’s disease, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731246</guid>
      <pubDate>Thu, 21 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731246-nampt-activators-disclosed-in-nanjing-reju-therapeutics-patent</link>
    </item>
    <item>
      <title>As IVL technologies advance, Shockwave looks to defend its lead</title>
      <description>
        <![CDATA[As interests and competition in the intravascular lithotripsy (IVL) market heats up, Shockwave Medical Inc. said it believes that its latest coronary IVL catheter, the C2 Aero, and other projects in the pipeline, will help it to maintain its leadership in calcium modification.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731372</guid>
      <pubDate>Thu, 21 May 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731372-as-ivl-technologies-advance-shockwave-looks-to-defend-its-lead</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Shockwave-C2-Aero-IVL-5-21.webp?t=1779396208" type="image/jpeg" medium="image" fileSize="82703">
        <media:title type="plain">Shockwave Medical - C2 Aero coronary IVL</media:title>
        <media:description type="plain">C2 Aero coronary IVL catheter. Credit: Shockwave Medical Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Subgroup analysis of the Champion-AF trial shows age not a factor</title>
      <description>
        <![CDATA[A subgroup analysis of data from Boston Scientific Corp.’s Champion-AF trial, which looked at the outcomes for patients with atrial fibrillation treated with a left atrial appendage closure (LAAC) device compared to direct oral anticoagulants (DOACs), found that the efficacy and safety of LAAC compared to DOAC are not affected by age. The data were presented at the EuroPCR conference in Paris.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731344</guid>
      <pubDate>Wed, 20 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731344-subgroup-analysis-of-the-champion-af-trial-shows-age-not-a-factor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Boston-Scientific-Watchman-FLX-.webp?t=1779309137" type="image/jpeg" medium="image" fileSize="104199">
        <media:title type="plain">Boston Scientific Watchman FLX</media:title>
        <media:description type="plain">Watchman FLX left atrial appendage closure device. Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>All Women data show Allegra edge in female TAVR patients</title>
      <description>
        <![CDATA[Data from the All Women clinical trial, which looked at the Allegra transcatheter aortic valve replacement (TAVR) system compared to balloon-expandable valves (BEV) in women with aortic stenosis, showed that Allegra delivered lower mean gradients and less prosthesis-patient mismatch than BEVs. The data presented at the EuroPCR conference in Paris was the first randomized head-to-head comparison of different TAVR platforms conducted exclusively in women.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731340</guid>
      <pubDate>Wed, 20 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731340-all-women-data-show-allegra-edge-in-female-tavr-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Biosensors-International-Allegra-transcatheter-heart-valve-5-20.webp?t=1779308345" type="image/jpeg" medium="image" fileSize="73313">
        <media:title type="plain">Biosensors International Allegra transcatheter heart valve</media:title>
        <media:description type="plain">Allegra transcatheter heart valve. Credit: Biosensors International </media:description>
      </media:content>
    </item>
    <item>
      <title>‘Detargeted’ targeted gene therapy improves activity in Pompe</title>
      <description>
        <![CDATA[A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme and the vector that delivers it to the target tissue while avoiding the liver. The findings suggest that combining an optimized transgene with a targeted capsid could significantly enhance the effectiveness of gene therapy for Pompe disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731174</guid>
      <pubDate>Wed, 20 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731174-detargeted-targeted-gene-therapy-improves-activity-in-pompe</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Acid-alpha-glucosidase-molecular-structure.webp?t=1779288468" type="image/jpeg" medium="image" fileSize="390572">
        <media:title type="plain">Acid alpha-glucosidase molecular structure isolated on black</media:title>
      </media:content>
    </item>
    <item>
      <title>Medical devices evolving into intelligent, adaptive systems</title>
      <description>
        <![CDATA[The convergence of robotics, sensors and AI is reshaping how medical devices interact with patients, clinicians and healthcare systems. Across the field, from oncology to cardiology and women’s health, companies are integrating software, connectivity, data analytics and biological information into their products. And although traditional devices, such as screws for orthopedics or valves for cardiology, remain essential, the shift underway is leading to much more personalized medicine, which is more effective and safer, Eran Lerer, managing partner, at Shoni Health Ventures, told <em>BioWorld</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731366</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731366-medical-devices-evolving-into-intelligent-adaptive-systems</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Feminai-patch-and-app-5-14.webp?t=1778791522" type="image/jpeg" medium="image" fileSize="86374">
        <media:title type="plain">Feminai patch and app</media:title>
        <media:description type="plain">Feminai Ltd. combines a disposable wearable patch with an app to help women screen for breast cancer at home. Credit: Feminai Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal </title>
      <description>
        <![CDATA[Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage Alzheimer’s disease (AD) therapy, AR-1001. The option fee plus license agreement has potential to tally $4.7 billion for Aribio, marking the largest deal for an AD asset inked by a Korean biotech company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731362</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731362-fosun-secures-rights-to-aribios-ar-1001-in-potential-47b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration.webp?t=1755091469" type="image/png" medium="image" fileSize="522090">
        <media:title type="plain">Doctor with brain illustration, businessman with dollar sign illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Elixir Dynamx system sees lower event rates than drug-eluting stent</title>
      <description>
        <![CDATA[Elixir Medical Corp. reported four-year data from the Bioadaptor randomized controlled trial presented at the EuroPCR conference in Paris, which showed that patients with coronary artery disease treated with its Dynamx coronary drug-eluting bioadaptor system experienced significantly lower event rates compared to those treated with Medtronic plc’s Resolute Onyx drug-eluting stent, including reduction in cardiovascular death.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731329</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731329-elixir-dynamx-system-sees-lower-event-rates-than-drug-eluting-stent</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Elixir-Medical-DynamX-21may25.webp?t=1779219759" type="image/jpeg" medium="image" fileSize="273431">
        <media:title type="plain">Elixir Medical DynamX</media:title>
        <media:description type="plain">Dynamx coronary drug-eluting bioadaptor system. Credit: Elixir Medical Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Boston Scientific reports Seismiq IVL data from Fracture study</title>
      <description>
        <![CDATA[Boston Scientific Corp. reported positive results from the Fracture investigational device exemption trial which evaluated its Seismiq 4CE coronary intravascular lithotripsy (IVL) catheter in patients with severely calcified coronary artery disease. Late-breaking data presented at the EuroPCR conference in Paris showed that the pivotal study met its primary safety and effectiveness endpoints, with high rates of freedom from major adverse cardiac events at 30 days and strong procedural success.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731328</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731328-boston-scientific-reports-seismiq-ivl-data-from-fracture-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Boston-Sci-Seismiq-4CE-coronary-IVL-catheter-5-19.webp?t=1779222476" type="image/jpeg" medium="image" fileSize="67429">
        <media:title type="plain">Boston Sci Seismiq 4CE coronary IVL catheter</media:title>
        <media:description type="plain">Seismiq 4CE coronary IVL catheter. Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Boston Sci invests $1.5B in Mirus, gains option for TAVR system </title>
      <description>
        <![CDATA[Boston Scientific Corp. has invested $1.5 billion for a 34% equity stake in Mirus LLC in a deal under which it is also gaining an exclusive option to acquire the Siegel balloon expandable transcatheter aortic valve replacement (TAVR) system.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731314</guid>
      <pubDate>Mon, 18 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731314-boston-sci-invests-15b-in-mirus-gains-option-for-tavr-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Mirus-Siegel-TAVR-5-18.webp?t=1779132172" type="image/jpeg" medium="image" fileSize="79457">
        <media:title type="plain">Mirus Siegel TAVR</media:title>
        <media:description type="plain">Siegel balloon expandable TAVR) system. Credit: Mirus LLC</media:description>
      </media:content>
    </item>
    <item>
      <title>New hypertension option as Astrazeneca’s Baxfendy wins FDA nod</title>
      <description>
        <![CDATA[Patients on antihypertensive medications who still struggle with high blood pressure now have a new treatment option, following the U.S. FDA’s approval of Astrazeneca plc’s baxdrostat. Branded Baxfendy, the drug is a first-in-class aldosterone synthase inhibitor, though it could be joined soon by potential competitor Mineralys Therapeutics Inc., which has a December 2026 PDUFA date for its aldosterone synthase inhibitor, lorundrostat.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731309</guid>
      <pubDate>Mon, 18 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731309-new-hypertension-option-as-astrazenecas-baxfendy-wins-fda-nod</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Blood-pressure-cuff.webp?t=1709666702" type="image/png" medium="image" fileSize="439332">
        <media:title type="plain">Blood pressure cuff </media:title>
      </media:content>
    </item>
    <item>
      <title>Validity of Actelion patent hinges on temperature </title>
      <description>
        <![CDATA[Temperature matters when determining pH levels. Whether that level should be measured at a standard room temperature or refrigerated matters even more, at least in Actelion Ltd.’s infringement litigation against Mylan Inc. According to Johnson & Johnson’s Actelion, the pH level in epoprostenol, the key ingredient in its hypertension drug Veletri, should be measured at a refrigerated temperature when it comes to Mylan’s generic formulation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731211</guid>
      <pubDate>Fri, 15 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731211-validity-of-actelion-patent-hinges-on-temperature</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/pH-testing.webp?t=1778865955" type="image/jpeg" medium="image" fileSize="74585">
        <media:title type="plain">Test tube and pH chart</media:title>
      </media:content>
    </item>
    <item>
      <title>Medical devices evolving into intelligent, adaptive systems</title>
      <description>
        <![CDATA[The convergence of robotics, sensors and AI is reshaping how medical devices interact with patients, clinicians and healthcare systems. Across the field, from oncology to cardiology and women’s health, companies are integrating software, connectivity, data analytics and biological information into their products. And although traditional devices, such as screws for orthopedics or valves for cardiology, remain essential, the shift underway is leading to much more personalized medicine, which is more effective and safer, Eran Lerer, managing partner, at Shoni Health Ventures, told <em>BioWorld</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731199</guid>
      <pubDate>Thu, 14 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731199-medical-devices-evolving-into-intelligent-adaptive-systems</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Feminai-patch-and-app-5-14.webp?t=1778791522" type="image/jpeg" medium="image" fileSize="86374">
        <media:title type="plain">Feminai patch and app</media:title>
        <media:description type="plain">Feminai Ltd. combines a disposable wearable patch with an app to help women screen for breast cancer at home. Credit: Feminai Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal </title>
      <description>
        <![CDATA[Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage Alzheimer’s disease (AD) therapy, AR-1001. The option fee plus license agreement has potential to tally $4.7 billion for Aribio, marking the largest deal for an AD asset inked by a Korean biotech company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731194</guid>
      <pubDate>Thu, 14 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731194-fosun-secures-rights-to-aribios-ar-1001-in-potential-47b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration.webp?t=1755091469" type="image/png" medium="image" fileSize="522090">
        <media:title type="plain">Doctor with brain illustration, businessman with dollar sign illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>KHN-921 gains IND clearance for &lt;em&gt;MYBPC3&lt;/em&gt;-associated HCM</title>
      <description>
        <![CDATA[Chengdu Origen Biotechnology Co. Ltd. and Vanotech Ltd. have announced IND clearance by the FDA for KHN-921 for the treatment of hypertrophic cardiomyopathy (HCM) associated with <em>MYBPC3</em> mutations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731095</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731095-khn-921-gains-ind-clearance-for-emmybpc3-em-associated-hcm</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Abstract-blue-human-heart-with-red-cardio-pulse-line-and-red-circle.webp?t=1752266610" type="image/png" medium="image" fileSize="259569">
        <media:title type="plain">Abstract blue human heart with red cardio pulse line and red circle</media:title>
      </media:content>
    </item>
    <item>
      <title>China med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133M</title>
      <description>
        <![CDATA[Star Sports Medicine Co. Ltd. debuted on the Hong Kong Stock Exchange with an HK$829.55 million (US$105.86 million) IPO May 5, with shares closing about 118% higher on the first day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731227</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731227-china-med-tech-raises-star-sports-105m-ipo-cofoe-nabs-133m</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/HK-Star-Sports-IPO-5-6.webp?t=1778095416" type="image/jpeg" medium="image" fileSize="144071">
        <media:title type="plain">​Star Sports Medicine HKEX IPO ceremony</media:title>
        <media:description type="plain">Star Sports Medicine's IPO ceremony on May 5.
Credit: HKEX; x.com – @HKEXGroup</media:description>
      </media:content>
    </item>
    <item>
      <title>China med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133M</title>
      <description>
        <![CDATA[Star Sports Medicine Co. Ltd. debuted on the Hong Kong Stock Exchange with an HK$829.55 million (US$105.86 million) IPO May 5, with shares closing about 118% higher on the first day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730868</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730868-china-med-tech-raises-star-sports-105m-ipo-cofoe-nabs-133m</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/HK-Star-Sports-IPO-5-6.webp?t=1778095416" type="image/jpeg" medium="image" fileSize="144071">
        <media:title type="plain">​Star Sports Medicine HKEX IPO ceremony</media:title>
        <media:description type="plain">Star Sports Medicine's IPO ceremony on May 5.
Credit: HKEX; x.com – @HKEXGroup</media:description>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026 kicks off with spotlight on oligonucleotides</title>
      <description>
        <![CDATA[Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and the promise of “programmable,” precision medicine for patients, speakers at Bio Korea 2026 said April 28.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730927</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730927-bio-korea-2026-kicks-off-with-spotlight-on-oligonucleotides</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Researcher-antisense-oligonucleotides.webp?t=1775662140" type="image/jpeg" medium="image" fileSize="579461">
        <media:title type="plain">AI generated image for researcher developing antisense oligonucleotides</media:title>
      </media:content>
    </item>
    <item>
      <title>Cytokinetics metrics satisfy in nHCM phase III</title>
      <description>
        <![CDATA[Thanks to a trial design that, according to Evercore ISI analyst Cory Kasimov, “played out exactly as drawn up,” Cytokinetics Inc. hit both of the phase III co-primary endpoints with aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730848</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730848-cytokinetics-metrics-satisfy-in-nhcm-phase-iii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardio-heart-attack.webp?t=1595367448" type="image/png" medium="image" fileSize="363148">
        <media:title type="plain">Heart illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Vanderbilt patent describes 5-HT2B receptor antagonists</title>
      <description>
        <![CDATA[Vanderbilt University has identified new 1-heteroarylazetidine-3-heteroarylmethylcarboxamide 5-HT2B receptor antagonists reported to be useful for the treatment of myocardial infarction, systemic sclerosis and pulmonary arterial hypertension.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730824</guid>
      <pubDate>Mon, 04 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730824-vanderbilt-patent-describes-5-ht2b-receptor-antagonists</link>
    </item>
    <item>
      <title>Quintuple GLP-1-GIP-PPAR agonist for obesity and diabetes control</title>
      <description>
        <![CDATA[A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome proliferator activated receptors (PPAR α/γ/δ). GLP-1-GIP-Lani enables targeted delivery of the PPAR agonist to cells that express incretin receptors, enhancing weight loss, improving glucose control and reducing inflammation in obese mice. In these models, it surpassed the effects of GLP-1 receptor agonists such as semaglutide and GLP-1-GIP co-agonists such as tirzepatide in reducing body weight, improving glycemic control and enhancing metabolic outcomes during active treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730790</guid>
      <pubDate>Thu, 30 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730790-quintuple-glp-1gipppar-agonist-for-obesity-and-diabetes-control</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Glucagon-like-peptide-1-receptor-GLP-1R-binding-site-small-molecule-agonist.webp?t=1777564710" type="image/jpeg" medium="image" fileSize="637678">
        <media:title type="plain">Glucagon-like peptide-1 receptor (GLP-1R) complex</media:title>
        <media:description type="plain">Glucagon-like peptide-1 receptor (GLP-1R) complex, representing the molecular target for GLP-1 agonists. Detailed view of the binding site with small-molecule agonist.</media:description>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026 kicks off with spotlight on oligonucleotides</title>
      <description>
        <![CDATA[Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and the promise of “programmable,” precision medicine for patients, speakers at Bio Korea 2026 said April 28.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730686</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730686-bio-korea-2026-kicks-off-with-spotlight-on-oligonucleotides</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Researcher-antisense-oligonucleotides.webp?t=1775662140" type="image/jpeg" medium="image" fileSize="579461">
        <media:title type="plain">AI generated image for researcher developing antisense oligonucleotides</media:title>
      </media:content>
    </item>
    <item>
      <title>Supremes weigh in on skinny labels in long-awaited argument </title>
      <description>
        <![CDATA[The U.S. Supreme Court’s ruling in <em>Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc.</em> could either discourage the development of generic drugs under a skinny label or make innovators think long and hard about investing hundreds of millions of dollars in developing new indications for drugs already on the market.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730682</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730682-supremes-weigh-in-on-skinny-labels-in-long-awaited-argument</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Decorative-scales-of-justice-in-a-courtroom.webp?t=1755117951" type="image/jpeg" medium="image" fileSize="658777">
        <media:title type="plain">Decorative scales of justice in a courtroom</media:title>
      </media:content>
    </item>
    <item>
      <title>Med-tech companies highlight PFA data as competition intensifies </title>
      <description>
        <![CDATA[New data on pulsed field ablation (PFA) presented at Heart Rhythm 2026 in Chicago over the weekend continue to show the benefits and superiority of the technologies in treating patients with atrial fibrillation. The PFA landscape is fast-evolving and med-tech players are jostling for market share with ever-differentiated platforms looking to attract electrophysiologists.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730642</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730642-med-tech-companies-highlight-pfa-data-as-competition-intensifies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Atrial-fibrillation-illustration.webp?t=1620156165" type="image/png" medium="image" fileSize="398365">
        <media:title type="plain">Atrial fibrillation illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Milestone in Atrium and BMS cardiovascular collaboration</title>
      <description>
        <![CDATA[Atrium Therapeutics Inc. has earned a $15 million development milestone payment from Bristol Myers Squibb Co. (BMS) for the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the companies’ ongoing collaboration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730635</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730635-milestone-in-atrium-and-bms-cardiovascular-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Vacsular-system.webp?t=1639599093" type="image/png" medium="image" fileSize="555720">
        <media:title type="plain">Vascular system</media:title>
      </media:content>
    </item>
  </channel>
</rss>
